^
Association details:
| Biomarker: | TGFB1 underexpression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Bavencio (avelumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
699O - Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers
Published date:
09/19/2020
Excerpt:
In pts with elevated immune gene expression signatures, lower TGFb expression was associated with greater OS benefit with avelumab.
